| [PMID]: | 28749536 |
| [Au] Autor: | Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ |
| [Ad] Endereço: | Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. |
| [Ti] Título: | The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide. |
| [So] Source: | Cancer;123(22):4356-4362, 2017 Nov 15. |
| [Is] ISSN: | 1097-0142 |
| [Cp] País de publicação: | United States |
| [La] Idioma: | eng |
| [Ab] Resumo: | BACKGROUND: Interactions between industry and prescribers have raised concerns regarding conflicts of interest. To the best of the authors' knowledge, quantitative data measuring these interactions have been limited until recently. In the current study, the authors sought to determine whether an association exists between industry payments and prescriber behavior with regard to abiraterone and enzalutamide. METHODS: Two Centers for Medicare and Medicaid Services databases were combined to analyze oncologists and urologists who received industry payments and/or prescribed abiraterone and enzalutamide. Correlation analysis was constructed on prescription count and industry payments. Multivariable median regression examined predictors of change in prescription count per dollar of industry payment. Stratifying prescribers by quantile evaluated threshold effects on prescribers. RESULTS: The number of prescriptions was similar between prescribers who did and those who did not receive industry payment for both drugs. The median industry payment amount to prescribers differed between prescribers and nonprescribers for abiraterone ($72 vs $56) and enzalutamide ($59 vs $31). Although no statistical association was found to exist between industry payment amount and prescription count for abiraterone prescribers, an association was found to exist for enzalutamide prescribers (rho = 0.31). A small change was found with regard to prescription count per dollar of industry payment for abiraterone (0.0007 prescriptions) and enzalutamide (0.0006 prescriptions). The amount of industry payment needed to predict one additional prescription was found to be lower in the fourth and fifth quantiles compared with the first through third quantiles. CONCLUSIONS: No difference in prescription count was found to exist between prescribers who received industry payments and those who did not. A positive correlation was noted between industry payments and prescription count for enzalutamide. Ease of adoption may affect differences between the 2 drugs. Cancer 2017;123:4356-62. © 2017 American Cancer Society. |
| [Mh] Termos MeSH primário: |
Androstenos/economia
Androstenos/uso terapêutico
Indústria Farmacêutica/economia
Medicare/economia
Feniltioidantoína/análogos & derivados
Padrões de Prática Médica/economia
|
| [Mh] Termos MeSH secundário: |
Conflito de Interesses
Custos de Medicamentos
Indústria Farmacêutica/ética
Ética Médica
Gastos em Saúde/estatística & dados numéricos
Seres Humanos
Revisão da Utilização de Seguros
Medicare/estatística & dados numéricos
Feniltioidantoína/economia
Feniltioidantoína/uso terapêutico
Médicos/economia
Médicos/ética
Padrões de Prática Médica/ética
Estados Unidos/epidemiologia
|
| [Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Androstenes); 0 (MDV 3100); 2010-15-3 (Phenylthiohydantoin); G819A456D0 (abiraterone) |
| [Em] Mês de entrada: | 1711 |
| [Cu] Atualização por classe: | 171128 |
[Lr] Data última revisão:
| 171128 |
| [Sb] Subgrupo de revista: | AIM; IM |
| [Da] Data de entrada para processamento: | 170728 |
| [St] Status: | MEDLINE |
| [do] DOI: | 10.1002/cncr.30914 |
| |
|
